Results 81 to 90 of about 123,859 (259)
Addiction, EarlyView.Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock +8 more
wiley +1 more source
Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era
Addiction, EarlyView.Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley +1 more source
Varenicline for cannabis use disorder: A randomized controlled trial
Addiction, EarlyView.Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy +11 more
wiley +1 more source
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Objectives Central poststroke pain (CPSP), a neuropathic pain condition, is difficult to treat. Repetitive transcranial magnetic stimulation (rTMS) targeted to the primary motor cortex (M1) can alleviate the condition, but not all patients respond. We aimed to assess a promising alternative rTMS target, the secondary somatosensory cortex (S2),
Juhani Ojala +10 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer +16 more
wiley +1 more source
, 2016 Report containing non-financial data for the Texas Alcoholic Beverage Commission during fiscal year 2016, including information related to strategic plan goals, indirect costs and fees, spaces and vehicles used by the agency, and other reportable ...
Texas Alcoholic Beverage Commission
core
Addiction, EarlyView.Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove +3 more
wiley +1 more source
Addiction, EarlyView.Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung +8 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien +15 more
wiley +1 more source